Express Mail Label No.: EM103214657US Attorney Docket No.: 27353-513-US1

and of Deposit: May 8, 2009

1

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number: 10/532,834 Confirmation No.: 8870

Applicants : Jonathan Michael **BLACKBURN**, et al.

Filed: February 16, 2006

TC/A.U. : 1656

Examiner : Marsha M. **TSAY**Attorney Docket No. : 27353-513-US1

For : NEW USES OF PROTEINS ENCODED BY BLE GENES

AND ANTIBIOTICS FROM THE BLEOMYCIN FAMILY

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 in the above-identified application. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. publication and U.S. patents are not required.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Express Mail Label No.: EM103214657US Attorney Docket No.: 27353-513-US1

Date of Deposit: May 8, 2009

Applicants: Jonathan Michael Blackburn, et al.

U.S.S.N.: 10/532,834

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by

35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment, to Deposit Account No. Deposit Account No. 50-0311, Reference No. 27353-513-US1, Customer No. 35437.

Respectfully submitted,

Ilonu Gont

Dated: May 8, 2009

Ivor R. Elrifi, Reg. No. 39,529 Ilona Gont, Reg. No. 58,714 Attorney/Agent for Applicants c/o MINTZ, LEVIN, COHN, FERRIS, et al. 666 Third Avenue, 24th Floor

New York, New York 10017 Telephone: (212) 935-3000 Telefax: (212) 983-3115